



Published in final edited form as:

Science. 2009 August 21; 325(5943): 1006–1010. doi:10.1126/science.1175870.

Bcl6 and Blimp-1 Are Reciprocal and Antagonistic Regulators of T Follicular Helper Cell Differentiation

Robert J. Johnston^{1,2,*}, Amanda C. Poholek^{3,*}, Daniel DiToro¹, Isharat Yusuf¹, Danelle Eto¹, Burton Barnett¹, Alexander L. Dent⁴, Joe Craft^{5,6}, and Shane Crotty^{1,2,†}

¹Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology (LIAI), 9420 Athena Circle, La Jolla, CA 92037, USA.

²Department of Medicine, University of California, San Diego School of Medicine, La Jolla, CA 92037, USA.

³Department of Cell Biology, Yale University School of Medicine, New Haven, CT 06520, USA.

⁴Department of Microbiology and Immunology and Walther Oncology Center, Indiana University School of Medicine, Indianapolis, IN 46202, USA.

⁵Department of Immunobiology, Yale University School of Medicine, New Haven, CT 06520, USA.

⁶Section of Rheumatology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT 06520, USA.

Abstract

Effective B cell–mediated immunity and antibody responses often require help from CD4⁺ T cells. It is thought that a distinct CD4⁺ effector T cell subset, called T follicular helper cells (T_{FH}), provides this help; however, the molecular requirements for T_{FH} differentiation are unknown. We found that expression of the transcription factor Bcl6 in CD4⁺ T cells is both necessary and sufficient for in vivo T_{FH} differentiation and T cell help to B cells in mice. In contrast, the transcription factor Blimp-1, an antagonist of Bcl6, inhibits T_{FH} differentiation and help, thereby preventing B cell germinal center and antibody responses. These findings demonstrate that T_{FH} cells are required for proper B cell responses in vivo and that Bcl6 and Blimp-1 play central but opposing roles in T_{FH} differentiation.

Each lineage of effector CD4⁺ T cells (T_{H1}, T_{H2}, T_{H17}, and T_{reg}) is defined and controlled by a unique master regulator transcription factor (T-bet, GATA3, RORγt, and Foxp3, respectively) (1). A proposed fifth effector subset, T follicular helper (T_{FH}) cells, is thought to provide help for the generation of B cell–mediated immune responses, including class switch recombination, germinal center differentiation, and affinity maturation (2). Here, we identified Bcl6 as a T_{FH} master regulator and found that germinal center formation does not occur in the absence of T_{FH} cells.

Copyright 2009 by the American Association for the Advancement of Science; all rights reserved.

†To whom correspondence should be addressed. shane@liai.org.

*These authors contributed equally to this work.

Supporting Online Material

www.sciencemag.org/cgi/content/full/1175870/DC1

Methods

Table S1

Figs. S1 to S14

References

T_{FH} cells are well described phenotypically in humans, and more recently in mice, as expressing high levels of the chemokine receptor CXCR5 and molecules such as ICOS, PD1, interleukin-21 (IL-21), and BTLA (2–9). Given that CD4⁺ T cells can up-regulate CXCR5 and/or ICOS after activation (2,10), it is important to phenotypically distinguish T_{FH} from highly activated CD4⁺ T cells. We identified T_{FH} cells in mice in the context of acute infection with lymphocytic choriomeningitis virus (LCMV) by adoptively transferring T cell receptor (TCR) transgenic T cells specific for the LCMV epitope gp66-77 in the context of major histocompatibility complex (MHC) class II molecule I-A^b (SMtg). T_{FH} cells were CXCR5^{high} ICOS^{high} PD1^{high} BTLA^{high} CD200^{high} SLAM^{low} (Fig. 1, A and B, and fig. S1) and capable of producing IL-21 (Fig. 1C). We confirmed these results for polyclonal LCMV-specific CD4⁺ T cell responses (fig. S2). CXCR5 is the receptor for the B cell follicle chemokine CXCL13 (11), and T_{FH} cells were selectively able to migrate in response to CXCL13 in vitro (Fig. 1D), consistent with the importance of CXCR5 for T_{FH} (6,12).

To understand how T_{FH} differentiation is transcriptionally regulated, we performed gene expression microarray analysis of virus-specific T_{FH} and non-T_{FH} effector CD4⁺ T cells (Fig. 1E and figs. S3 and S4). Notably, the transcription factor B cell CLL/lymphoma 6 (Bcl6) was strongly up-regulated in T_{FH} (Fig. 1E). This is in agreement with previous reports of elevated Bcl6 expression in murine and human T_{FH} cells (3–5,8). Furthermore, Blimp-1 (*prdm1*) was the most down-regulated transcription factor in T_{FH} cells (fig. S4), consistent with a recent report (13). Bcl6 is essential for germinal center B cell differentiation (14–16), and Blimp-1 is well characterized as an antagonist of Bcl6 that can also be directly repressed by Bcl6 (16–20). Up-regulation of Bcl6 mRNA (Fig. 1F) and down-regulation of Blimp-1 mRNA (Fig. 1G) were confirmed by quantitative polymerase chain reaction (qPCR). Bcl6 protein expression was detected in germinal center CD4⁺ T cells (fig. S2), consistent with previous observations in human lymphoid tissue (4,21).

Although Bcl6 mRNA expression has been correlated with T_{FH}, no experimental data supporting a specific role for Bcl6 in T_{FH} differentiation have been reported. We expressed Bcl6 in SMtg CD4⁺ T cells via a retroviral vector (RV) with a bicistronic mRNA coexpressing green fluorescent protein (GFP) (fig. S5). Transduced Bcl6-RV⁺ SMtg and control untransduced SMtg CD4⁺ T cells were transferred into naïve C57BL/6 hosts, which were subsequently infected with LCMV, and T_{FH} differentiation was examined (Fig. 2, A to E). Bcl6 expression drove nearly absolute T_{FH} differentiation in vivo (80 to 90%; Fig. 2, B and C), in contrast to T_{FH} differentiation in control untransduced (GFP⁻) SMtg cells in the same mice (Fig. 2B) or mice that received SMtg transduced with a control retrovirus expressing only GFP (GFP-RV⁺) and untransduced SMtg in equal proportions (Fig. 2C). Comparably striking results were seen in studies where only Bcl6-RV⁺ or GFP-RV⁺ SMtg CD4⁺ T cells were transferred into host mice (fig. S6). Bcl6 overexpression did not affect T cell expansion in vivo (fig. S5). Constitutive expression of Bcl6 drove up-regulation of CXCR5, PD-1, ICOS, CD200, and BTLA expression (Fig. 2, D and E, and fig. S6), as well as the inhibition of SLAM and Blimp-1 (fig. S6; see below). These results indicate that Bcl6 expression drives full T_{FH} differentiation in vivo.

T_{FH} differentiation is known to require the presence of B cells and is thought to require the presence of antigen-specific B cells (6). We thus hypothesized that Bcl6 expression induced by interaction with antigen-specific B cells could be the event that commits a T cell to T_{FH} differentiation. To test this, we examined whether Bcl6 expression in CD4⁺ T cells was sufficient to drive T_{FH} differentiation in μ MT B cell-deficient mice and in B cell receptor (BCR) transgenic mice of an irrelevant specificity (MD4, specific for hen egg lysozyme). GFP-RV⁺ SMtg CD4⁺ T cells failed to differentiate into T_{FH} in μ MT or MD4 mice infected with LCMV (Fig. 2, F and G), which demonstrates that T_{FH} differentiation in the context of a viral infection is dependent on the presence of antigen-specific B cells. In contrast, Bcl6-RV⁺ SMtg

cells differentiated into T_{FH} in the absence of antigen-specific B cells or even in the total absence of B cells (Fig. 2, F and G). These results indicate that cognate T-B interactions induce Bcl6 expression in CD4⁺ T cells and that Bcl6 is sufficient to drive T_{FH} differentiation, even in the absence of such interactions.

T_{FH} cells are thought to provide B cell help in vivo (2,22). We assessed the capacity of Bcl6-RV⁺ SMtg CD4⁺ T cells to help B cells in vivo by examining germinal center development in LCMV-infected mice. Overexpression of Bcl6 increased the already robust frequency of germinal center B cells after LCMV infection (Fig. 3, A and B). As an additional measure of B cell help, we also examined the role of Bcl6 in T cell-dependent antibody production. Constitutive expression of Bcl6 in OT-II CD4⁺ T cells enhanced NP-Ova serum immunoglobulin G (IgG) responses (Fig. 3C and fig. S7), which were sustained (Fig. 3C). Our results suggest that Bcl6 was specifically enhancing T_{FH} differentiation and not skewing the T_{H1}/T_{H2} profile of the CD4⁺ T cells, because all IgG isotypes were enhanced in the mice receiving Bcl6-expressing OT-II CD4⁺ T cells, with the strong IgG1 dominance maintained (fig. S7).

The results of these experiments showed that Bcl6 expression was sufficient to drive the differentiation of functional T_{FH}. To test whether Bcl6 was also necessary for T_{FH} differentiation, we examined *Bcl6*^{-/-} CD4⁺ T cells. *Bcl6*^{-/-} mice have an abundance of highly activated CD4⁺ T cells (fig. S8) and succumb to early mortality (14,15). To circumvent these issues, we transferred *Bcl6*^{+/+} or *Bcl6*^{-/-} OT-II bone marrow into irradiated C57BL/6 recipients (fig. S8). *Bcl6*^{-/-} OT-II CD4⁺ T cells obtained from chimeric mice did not exhibit lymphoproliferation or spontaneous activation upon transfer into C57BL/6 mice (fig. S8, D to F). *Bcl6*^{-/-} or *Bcl6*^{+/+} OT-II recipient mice were subsequently immunized with Ova in alum. Strikingly, *Bcl6*^{-/-} OT-II CD4⁺ T cells did not differentiate into T_{FH} cells (Fig. 3D). We hypothesized that if T_{FH} cells are necessary for B cell help in vivo, a cell-intrinsic CD4⁺ T cell block in T_{FH} differentiation should result in a failure to generate antigen-specific B cell responses such as germinal center formation. To test this hypothesis, we transferred *Bcl6*^{-/-} or *Bcl6*^{+/+} OT-II CD4⁺ T cells into *Icos*^{-/-} mice, which have ineffective B cell help (2,23). After NP-Ova immunization, *Icos*^{-/-} mice that received *Bcl6*^{-/-} OT-II CD4⁺ T cells were unable to form germinal centers, in contrast to mice that received wild-type OT-II CD4⁺ T cells (Fig. 3, E to G, and fig. S9). These data demonstrate that Bcl6 is necessary for T_{FH} differentiation and that T_{FH} cells are necessary for germinal center formation. Together, these results indicate that Bcl6 is a bona fide master regulator of T_{FH} differentiation in vivo.

Blimp-1 is a known antagonist of Bcl6, capable of directly inhibiting Bcl6 expression in B and T cells (17,18). Conversely, Blimp-1 expression can be inhibited by Bcl6 (16–18,20). On the basis of our observations that Bcl6 drives T_{FH} cell differentiation and function, and because Blimp-1 was the single most down-regulated transcription factor in T_{FH} cells by gene expression array analysis (Fig. 1E and fig. S4) and qPCR (Fig. 1G), we hypothesized a role for Blimp-1 in blocking T_{FH} differentiation in vivo. We constructed a Blimp-1 retroviral expression vector, Blimp1-RV (fig. S5), designed to express physiological levels of Blimp-1. Only CD4⁺ T cells expressing low levels of the GFP reporter were used for in vivo experiments (fig. S10A). Blimp-1 blocked Bcl6 protein expression in activated antigen-specific CD4⁺ T cells in vivo (Fig. 4A). To determine the effects of Blimp-1 on T_{FH} differentiation, we mixed Blimp1-RV⁺ SMtg CD4⁺ T cells and untransduced control SMtg cells in equal proportions and transferred them into host mice subsequently infected with LCMV. We observed normal proliferation of Blimp-1-expressing SMtg CD4⁺ T cells (fig. S10); however, T_{FH} differentiation was severely abrogated, with an 80% reduction in T_{FH} frequency (Fig. 4, B and C). Blockade of T_{FH} differentiation by Blimp-1 was also observed when mice separately received Blimp1-RV⁺ versus GFP-RV⁺ SMtg cells (fig. S10, F and G). Constitutive expression of Blimp-1 inhibited acquisition of the T_{FH} phenotype: SLAM expression was increased (Fig.

4D), whereas CXCR5, ICOS, and PD-1 expression were all decreased (Fig. 4D and fig. S10). Inhibition of T_{FH} differentiation by Blimp-1 was physiological and specific, because the expression levels of SLAM, ICOS, and PD-1 by Blimp1-RV⁺ SMtg CD4⁺ T cells were equivalent to the expression levels seen in wild-type activated non-T_{FH} SMtg CD4⁺ T cells, and not naïve cells (fig. S10I). Blimp1-RV⁺ and wild-type non-T_{FH} SMtg cells also expressed comparable amounts of the cytokines interferon- γ (IFN- γ) and IL-2 (fig. S11). High amounts of Blimp-1 expression can inhibit proliferation in B and T cells (17,24,25). The moderate level of Blimp-1 expression used in our experiments (fig. S10E) did not affect proliferation in vivo (fig. S10, C, D, and H), in agreement with previous in vitro studies (26) and our observation that non-T_{FH} CD4⁺ T cells express 20 times as much Blimp-1 as do T_{FH} cells and are still proliferative. Blimp-1 expression did not affect expression of the T helper lineage-specific transcription factors Foxp3, GATA3, and ROR γ t (fig. S11), which indicates that Blimp-1 did not induce differentiation into other helper lineages. Collectively, these data suggest that Blimp-1 acts specifically to repress Bcl6 and thus blocks T_{FH} differentiation.

Given that Blimp-1 is a physiological inhibitor of Bcl6 expression and T_{FH} differentiation in vivo, we performed an additional test of the necessity of T_{FH} for B cell help by transferring Blimp1-RV⁺ OT-II and GFP-RV⁺ OT-II CD4⁺ T cells into SAP-deficient (*sh2d1a*^{-/-}) mice [SAP-deficient mice exhibit a CD4⁺ T cell-intrinsic defect in germinal center formation (27–29)] subsequently immunized with NP-Ova. We observed germinal centers and anti-NP-Ova serum IgG in GFP-RV⁺ OT-II CD4⁺ T cell recipient mice after immunization (Fig. 4, E and F). Strikingly, although OT-II cell numbers were normal in Blimp1-RV⁺ OT-II recipient mice (fig. S12), germinal centers were reduced by 90% (Fig. 4E). Constitutive Blimp-1 expression also inhibited the NP-Ova-specific IgG response, reducing the serum antibody concentration to only 16% of normal levels (Fig. 4F). All IgG isotypes were reduced (fig. S12), confirming that Blimp-1 was specifically inhibiting T_{FH} differentiation. These results demonstrate both that Blimp-1 inhibits CD4⁺ T cell help to B cells and that T_{FH} cells are required for B cell help in vivo.

To confirm the biological role of Blimp-1 in inhibiting T_{FH} differentiation in vivo, we tested the ability of Blimp-1-deficient CD4⁺ T cells to differentiate into T_{FH}. To avoid autoimmunity complications (30,31), we deleted Blimp-1 (*prdm1*) in vitro in mature *prdm1*^{fl/fl} CD4⁺ T cells (32) by means of a Cre-expressing RV. We transferred Cre⁺ SMtg⁺ *prdm1*^{fl/fl} and control Cre⁻ SMtg⁺ *prdm1*^{fl/fl} CD4⁺ T cells into mice subsequently infected with LCMV. Deletion of *prdm1* substantially enhanced T_{FH} differentiation in vivo (Fig. 4G) without altering proliferation (fig. S13). These data indicate that Blimp-1 expression in vivo normally restricts Bcl6 expression and T_{FH} differentiation. In sum, our results reveal that Bcl6 and Blimp-1 are reciprocal master regulators of T_{FH} differentiation, with T_{FH} differentiation in vivo requiring the presence of Bcl6 and the absence of Blimp-1.

There has been extensive speculation about a role for Bcl6 in T_{FH} differentiation, based on gene expression data from human (2,4) and murine T_{FH} studies (3,8,9,13). Our data directly show that Bcl6 specifically drives T_{FH} differentiation and is a bona fide master regulator. The relationship between T_{FH} and other CD4⁺ T cell lineages has been a long-standing problem. The predominant CD4⁺ T cell response to LCMV is T_H1 (fig. S14), and it is notable that T-bet and IFN- γ were still expressed in the T_{FH} in vivo, although at lower levels than in T_H1/non-T_{FH} LCMV-specific CD4⁺ T cells (fig. S14). These observations are consistent with a model in which T_{FH} cells follow their own differentiation pathway but are not an isolated lineage and can exhibit partial characteristics of T_H1/T_H2 polarization depending on environmental conditions. This overlapping differentiation model would resolve the conundrum in the literature that neither T_H1, T_H2, nor T_H17 are required for B cell help in vivo (8,33,34), but that cells with T_H1, T_H2, or T_H17 phenotypes can provide B cell help in vivo (9,35–39).

The capacity for B cell help is a central attribute of CD4⁺ T cells and is a cornerstone of protective immunity. It is well known that in B cells, Bcl6 and Blimp-1 are powerful antagonistic master regulators of germinal center B cell differentiation and plasma cell differentiation. Our findings that Bcl6 and Blimp-1 also control T_{FH} differentiation illustrate the elegant use of the same antagonistic transcription factors to drive different functions in two lymphocyte populations differentiating in parallel: antigen-specific B cells and the T_{FH} cells that provide their help. Manipulation of these signaling pathways in vivo may have substantial therapeutic benefit for enhancing vaccines or, conversely, blocking auto-antibody responses.


Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

References and Notes


1. Zhu J, Paul WE. *Blood* 2008;112:1557. [PubMed: 18725574]
2. King C, Tangye S, Mackay C. *Annu. Rev. Immunol* 2008;26:741. [PubMed: 18173374]
3. Vinuesa CG, et al. *Nature* 2005;435:452. [PubMed: 15917799]
4. Chtanova T, et al. *J. Immunol* 2004;173:68. [PubMed: 15210760]
5. Rasheed AU, Rahn HP, Sallusto F, Lipp M, Müller G. *Eur. J. Immunol* 2006;36:1892. [PubMed: 16791882]
6. Haynes NM, et al. *J. Immunol* 2007;179:5099. [PubMed: 17911595]
7. Vogelzang A, et al. *Immunity* 2008;29:127. [PubMed: 18602282]
8. Nurieva RI, et al. *Immunity* 2008;29:138. [PubMed: 18599325]
9. Reinhardt RL, Liang HE, Locksley RM. *Nat. Immunol* 2009;10:385. [PubMed: 19252490]
10. Ansel KM, McHeyzer-Williams LJ, Ngo VN, McHeyzer-Williams MG, Cyster JG. *J. Exp. Med* 1999;190:1123. [PubMed: 10523610]
11. Ansel KM, et al. *Nature* 2000;406:309. [PubMed: 10917533]
12. Hardtke S, Ohl L, Förster R. *Blood* 2005;106:1924. [PubMed: 15899919]
13. Fazilleau N, McHeyzer-Williams LJ, Rosen H, McHeyzer-Williams MG. *Nat. Immunol* 2009;10:375. [PubMed: 19252493]
14. Ye BH, et al. *Nat. Genet* 1997;16:161. [PubMed: 9171827]
15. Dent AL, Shaffer AL, Yu X, Allman D, Staudt LM. *Science* 1997;276:589. [PubMed: 9110977]
16. Klein U, Dalla-Favera R. *Nat. Rev. Immunol* 2008;8:22. [PubMed: 18097447]
17. Martins G, Calame K. *Annu. Rev. Immunol* 2008;26:133. [PubMed: 18370921]
18. Cimmino L, et al. *J. Immunol* 2008;181:2338. [PubMed: 18684923]
19. Shaffer AL, et al. *Immunity* 2002;17:51. [PubMed: 12150891]
20. Shaffer AL, et al. *Immunity* 2000;13:199. [PubMed: 10981963]
21. Cattoretto G, et al. *Blood* 1995;86:45. [PubMed: 7795255]
22. Vinuesa CG, Tangye S, Moser B, Mackay C. *Nat. Rev. Immunol* 2005;5:853. [PubMed: 16261173]
23. Akiba H, et al. *J. Immunol* 2005;175:2340. [PubMed: 16081804]
24. Reljic R, Wagner SD, Peakman LJ, Fearon DT. *J. Exp. Med* 2000;192:1841. [PubMed: 11120780]
25. Martins GA, Cimmino L, Liao J, Magnusdottir E, Calame K. *J. Exp. Med* 2008;205:1959. [PubMed: 18725523]
26. Gong D, Malek TR. *J. Immunol* 2007;178:242. [PubMed: 17182561]
27. Crotty S, Kersh EN, Cannons J, Schwartzberg PL, Ahmed R. *Nature* 2003;421:282. [PubMed: 12529646]
28. Ma CS, Nichols KE, Tangye S. *Annu. Rev. Immunol* 2007;25:337. [PubMed: 17201683]
29. Schwartzberg PL, Mueller KL, Qi H, Cannons JL. *Nat. Rev. Immunol* 2009;9:39. [PubMed: 19079134]
30. Kallies A, et al. *Nat. Immunol* 2006;7:466. [PubMed: 16565720]

31. Martins GA, et al. *Nat. Immunol* 2006;7:457. [PubMed: 16565721]
32. Shapiro-Shelef M, et al. *Immunity* 2003;19:607. [PubMed: 14563324]
33. Tsiagbe, VK.; Thorbecke, GJ. *The Biology of Germinal Centers*. Thorbecke, GJ.; Tsiagbe, VK., editors. Springer-Verlag; Berlin: 1998. p. 1-103.
34. Kopf M, Le Gros G, Coyle AJ, Kosco-Vilbois M, Brombacher F. *Immunol. Rev* 1995;148:45. [PubMed: 8825282]
35. King IL, Mohrs M. *J. Exp. Med* 2009;206:1001. [PubMed: 19380638]
36. Zaretsky AG, et al. *J. Exp. Med* 2009;206:991. [PubMed: 19380637]
37. Hsu HC, et al. *Nat. Immunol* 2008;9:166. [PubMed: 18157131]
38. Smith KM, Brewer JM, Rush CM, Riley J, Garside P. *J. Immunol* 2004;173:1640. [PubMed: 15265892]
39. Smith KM, et al. *J. Immunol* 2000;165:3136. [PubMed: 10975827]
40. We thank R. Kageyama, L. Crickard, K. Hansen, C. Kim, and K. Van Gunst for technical assistance; S. Kaech for helpful discussions; A. Haberman and S. Kerfoot for technical help; and the NIH Tetramer Core for providing MHC class II tetramer reagents. Supported by LIAI institutional funds, a Pew Scholar Award, a Cancer Research Institute Award, and National Institute of Allergy and Infectious Diseases grants R01 072543 and NIAID R01 063107 (S.C.); Rheuminations Inc., the Arthritis Foundation, the Connecticut Chapter of the Lupus Foundation of America, and NIH grants AR40072, AR44076, and P30 AR053495 (J.C.); and fellowships from the UCSD/LIAI Immunology NIH Training Grant (I.Y. and R.J.J.). R.J.J. is a member of the UCSD Biomedical Sciences (BMS) graduate program. Microarray data have been deposited at the NCBI Gene Expression Omnibus (GSE16697). Author contributions are as follows: LCMV T_{FH} identification and microarrays, I.Y. and S.C.; Bcl6-RV and Blimp1-RV experiments, R.J.J., D.D., B.B.; T_{FH} migration, D.E.; Blimp-1 conditional knockout experiments, D.D.; Bcl6^{-/-} mice, A.L.D.; Bcl6^{-/-} experiments, A.C.P.; writing, S.C. (with intellectual and editorial contributions from the other authors); project conception and experimental design, S.C. and J.C.

**Fig. 1.**


Bcl6 is a T_{FH}-specific transcription factor. Naïve SMtg CD4⁺ T cells were transferred into B6 mice. In all panels, splenocytes were analyzed 8 days after infection with LCMV. (**A** and **B**) SMtg expression of CXCR5 and PD-1 (**A**) or SLAM (CD150) (**B**). SMtg⁺ (CD45.1⁺) CD4⁺ gated cells are shown. CXCR5^{high} T_{FH} cells are boxed in fluorescence-activated cell sorter (FACS) plots. Histogram overlays depict T_{FH} cells (red) as well as naïve CD4⁺ T cells (gray) and CXCR5^{low} non-T_{FH} SMtg cells (black). Data are representative of more than 10 independent experiments. (**C**) IL-21 mRNA in SMtg CD4⁺ T cells, normalized to the β-actin mRNA level ($\times 10^{-4}$). ** $P = 0.008$. (**D**) In vitro chemotaxis toward CXCL13 (BLC) by ex vivo SMtg CD4⁺ T cells. Results are expressed as percentages of SLAM^{low} T_{FH} SMtg (solid circles) and SLAM^{high} non-T_{FH} SMtg (open circles) that migrated in a transwell assay. *** $P \leq 0.001$. 1 μg, $P = 0.001$; 2 μg, $P = 0.0006$; 4 μg, $P = 0.0006$. Data are representative of three independent experiments; $n = 2$ per group. (**E**) Scatterplot of the average signal of biological replicates of T_{FH} versus non-T_{FH} SMtg gene expression microarray data. Blue lines indicate changes in gene expression by a factor of 3; 386 gene probes exhibited a factor of >3.0 increase in T_{FH}.

Data from one of two independent experiments are shown; $n = 2$ per group. **(F and G)** Quantitative reverse transcription PCR of Bcl6 (F) and Blimp-1 (G) mRNA expression, normalized to β -actin ($\times 10^{-4}$). *** $P < 0.0001$. Data are representative of four independent experiments; $n = 2$ per group. Error bars in all graphs are SEM.

**Fig. 2.**


Bcl6 expression is sufficient for T_{FH} differentiation in vivo. (A to E) Naïve SMtg CD4⁺ T cells were transduced with Bcl6-RV (Bcl6⁺) or left untransduced (control) and transferred into B6 mice subsequently infected with LCMV. (A) Gating of CD45.1⁺ untransduced SMtg (GFP⁻) and Bcl6-RV⁺ SMtg (GFP⁺) in the same host. CD4⁺ B220⁻ gate is shown. (B) T_{FH} (SLAM^{low} CXCR5^{high}, boxed) and non-T_{FH} (SLAM^{high} CXCR5^{low}) differentiation of untransduced SMtg (left) and Bcl6-RV⁺ SMtg (right). (C) Quantitation of SMtg T_{FH} differentiation. Mice received Bcl6-RV⁺ SMtg and untransduced SMtg, or GFP-RV⁺ and untransduced SMtg. “-,” untransduced; “+,” transduced with indicated RV. ****P* < 0.0001. Data are representative of three independent experiments; *n* = 4 per group. (D and E) CXCR5 expression (D) and PD-1 expression (E) on naïve CD4⁺ T cells (gray), GFP-RV⁺ SMtg (black), and Bcl6-RV⁺ SMtg (red). Bar graphs show mean fluorescence intensity (MFI) of naïve CD4⁺ T cells, GFP-RV⁺ SMtg non-T_{FH}, GFP-RV⁺ SMtg T_{FH}, and Bcl6-RV⁺ SMtg. For PD-1 MFI, non-T_{FH} versus T_{FH} or Bcl6-RV⁺, *P* < 0.05; T_{FH} versus Bcl6-RV⁺, *P* > 0.05. Data are representative of three independent experiments; *n* = 4 to 6 per group. (F and G) GFP-RV⁺ or Bcl6-RV⁺ SMtg cells were adoptively transferred separately into B cell-deficient mice (μMT) or HEL-specific BCR transgenic mice (MD4) on a μMT background. Host mice were subsequently infected with LCMV. Each group is a composite of three experiments; *n* = 2 (GFP-RV⁺ μMT), 6 (Bcl6-RV⁺ MD4), 6 (Bcl6-RV⁺ μMT), or 8 (GFP-RV⁺ MD4) per group.

(F) Differentiation of SMtg CD4⁺ T cells in MD4 BCR transgenic mice. T_{FH} cells (SLAM^{low} CXCR5^{high}) are boxed. CD4⁺ B220⁻ CD45.1⁺ GFP⁺ gate is shown. (G) Quantitation of SMtg T_{FH} differentiation. GFP-RV⁺ versus Bcl6-RV⁺ in MD4, ****P* < 0.0001. GFP-RV⁺ versus Bcl6-RV⁺ in μMT, ****P* < 0.0001.

**Fig. 3.**

Bcl6 expression is necessary for inducing T_{FH} B cell help in vivo. (A) Germinal center B cells (PNA⁺ Fas⁺, gated) in mice that received GFP-RV⁺ or Bcl6-RV⁺ SMTg CD4⁺ T cells and were subsequently infected with LCMV, analyzed at day 8 and gated on activated B cells (B220⁺ IgD^{low}). (B) Frequency of germinal center B cells of total splenocytes; $n = 4$ per group. Data are representative of three independent experiments. $*P = 0.029$. (C) GFP-RV⁺ or Bcl6-RV⁺ OT-II CD4⁺ T cells were transferred into B6 mice subsequently immunized with NP-Ova in alum. Control mice were immunized but received no OT-II cells. NP-Ova enzyme-linked immunosorbent assay (ELISA) was performed at day 15 and day 45; $n = 6$ per group. Data are representative of two independent experiments. Day 15 endpoint ELISA titers, $**P = 0.008$; day 45 endpoint ELISA titers, $*P = 0.017$. (D) Bcl6^{+/+} or Bcl6^{-/-} OT-II CD4⁺ T cells were transferred into congenically mismatched B6 mice subsequently immunized with Ova in alum. Splenocytes were analyzed 6 days after immunization; $n = 4$ per group. Data are representative of four independent experiments. OT-II⁺ CD44^{high} gate is shown. Quantitation of OT-II T_{FH} differentiation is also shown. $***P < 0.0001$. (E to G) Bcl6^{+/+} or Bcl6^{-/-} OT-II CD4⁺ T cells were cotransferred with B1-8 B cells into *Icos*^{-/-} mice subsequently immunized with NP-Ova in alum; $n = 2$ per group. Data are representative of two independent experiments. (E) Germinal

center B cells (PNA⁺ GL7⁺, boxed) 7 days after immunization. TCRβ⁻ IgD^{low} gate is shown. (F) Quantitation of GC B cells as percent of spleen. ***P* = 0.0015. (G) Germinal center histology. Spleen sections were stained with IgD (green), PNA (red), and CD4 (blue).

**Fig. 4.**

Blimp-1 and Bcl6 are antagonistic and reciprocal regulators of T_{FH} differentiation. **(A)** Immunoblot of Bcl6 protein expression (and β -actin control) in transduced SMtg $CD4^+$ T cells in vivo. **(B)** T_{FH} (SLAM^{low} CXCR5^{high}, boxed) differentiation of untransduced SMtg (left, “Control”) and Blimp1-RV⁺ SMtg (right, “Blimp-1⁺”) cells within a common host 8 days after LCMV infection. Gating is shown in fig. S10B. **(C)** Quantitation of SMtg T_{FH} differentiation. “-,” untransduced; “+,” transduced with the indicated RV. *** $P < 0.0001$; $n = 4$ per group. Data are representative of two independent experiments. **(D)** SLAM and CXCR5 expression by naïve $CD4^+$ T cells (gray), GFP-RV⁺ SMtg (black), and Blimp1-RV⁺ SMtg (red). **(E and F)** GFP-RV⁺ or Blimp1-RV⁺ OT-II $CD4^+$ T cells were transferred into SAP-deficient mice subsequently immunized with NP-Ova in alum; $n = 4$ per group. Data are representative of three independent experiments. **(E)** Germinal center B cells (PNA⁺ Fas⁺, gated) in mice that received GFP-RV⁺ or Blimp1-RV⁺ OT-II $CD4^+$ T cells. B220⁺ IgD^{low} gate is shown. Quantitation of germinal center B cells in the spleen is also shown. *** $P < 0.0001$. **(F)** NP-Ova IgG ELISA endpoint titers at day 10. * $P = 0.016$. **(G)** Purified naïve B6 and *prdm1^{fl/fl}* $CD45.2^+$ $CD4^+$ T cells were transduced with SMtg-RV, with or without Cre-RV (Cre⁺ or Cre⁻), sorted, and transferred into $CD45.1^+$ mice subsequently infected with LCMV. FACS plots depict T_{FH} (CXCR5^{high} SLAM^{low}, boxed) differentiation of control Cre⁺ SMtg⁺ B6 cells (left), Blimp-1-sufficient Cre⁻ SMtg⁺ *prdm1^{fl/fl}* cells (center), and Blimp-1-deficient Cre⁺ SMtg⁺ *prdm1^{fl/fl}* cells (right). $CD4^+$ $CD45.1^-$ $CD44^{\text{high}}$ 7AAD⁻ gate is shown. Quantitation of T_{FH} differentiation is also shown. Data are representative of two independent experiments. ** $P = 0.002$, *** $P = 0.0006$; $n = 4$ to 5 per group.